Contents
Article Outline
- Chapter 1
- Chapter 2
- Chapter 3
- Chapter 4
- Chapter 5
- Chapter 6
- Chapter 7
- Chapter 8
- Chapter 9
- Chapter 10
- Chapter 11
- Chapter 12
- Chapter 13
- Chapter 14
- Chapter 15
- Chapter 16
- Chapter 17
- Chapter 18
- Chapter 19
- Chapter 20
Cover Image: mTOR colocalizes with the Golgi apparatus. Colocalization of mTOR and the Golgi apparatus in Human Vascular Smooth Muscle Cells (HVSMC). Wild type mTOR (Flag-mTOR/pBJ5) was overexpressed in HVSMC by electroporation. The localization of mTOR in HVSMCs was determined by immunofluorescent staining with an anti-mTOR antibody (red, Cell Signalling (#2972), Danvers, MA). Anti-Golgin-97 antibody was used to detect the Golgi apparatus (green, Molecular Probes (A-21270), Leiden, The Netherlands). Shown is an image captured by scanning confocal microscopy. The yellow color shows colocalization of mTOR with Golgi apparatus. DAPI was used for DNA staining (nuclear compartment). (Robert J. Wagner, Eva M. Rzucidlo, M.D.)
GUEST EDITORS Richard J. Powell, Anton N. Sidawy, Michael T. Watkins
Preface 1A
Richard J. Powell, MD, Anton N. Sidawy, MD, and Michael T. Watkins, MD, Lebanon, NH; Washington, DC; and Boston, Mass
Chapter 1
Reviving the vascular surgeon–scientist: An interim assessment of the jointly sponsored Lifeline Foundation/National Heart, Lung, and Blood Institute William J. von Liebig Mentored Clinical Scientist Development (K08) Program 2A
Robert W. Thompson, MD, Beth Schucker, MS, K. Craig Kent, MD, Alexander W. Clowes, MD, Larry W. Kraiss, MD, John A. Mannick, MD, and James S. T. Yao, MD, St. Louis, Mo; Bethesda, Md; New York, NY; Seattle, Wash; Salt Lake City, Utah; Boston, Mass; and Chicago, Ill
Chapter 2
Translational control in endothelial cells 8A
Peter B. Brant-Zawadzki, MD, Douglas I. Schmid, MD, Huimao Jiang, MD, Andrew S. Weyrich, MD, Guy A. Zimmerman, MD, and Larry W. Kraiss, MD, Salt Lake City, Utah
Chapter 3
Smooth muscle cell signal transduction: Implications of vascular biology for vascular surgeons 15A
Akihito Muto, MD, PhD, Tamara N. Fitzgerald, MD, PhD, Jose M. Pimiento, MD, Stephen P. Maloney, MD, Desarom Teso, MD, Jacek J. Paszkowiak, MD, Tormod S. Westvik, MD, Fabio A. Kudo, MD, PhD, Toshiya Nishibe, MD, PhD, and Alan Dardik, MD, PhD, New Haven, Waterbury, and West Haven, Conn; and Toyoake, Aichi, Japan
Chapter 4
Regulation of vascular smooth muscle cell differentiation 25A
Eva M. Rzucidlo, MD, Kathleen A. Martin, PhD, and Richard J. Powell, MD, Lebanon, NH
Chapter 5
Integrin αvβ3 as a target in the prevention of neointimal hyperplasia 33A
Taku Kokubo, MD, Hisashi Uchida, MD, and Eric T. Choi, MD, St. Louis, Mo
Chapter 6
Angiogenesis and vasculogenesis: Inducing the growth of new blood vessels and wound healing by stimulation of bone marrow–derived progenitor cell mobilization and homing 39A
Omaida C. Velazquez, MD, Philadelphia, Pa
Chapter 7
The chemokine system in arteriogenesis and hind limb ischemia 48A
Paula K. Shireman, MD, San Antonio, Tex
Chapter 8
Clinical, cellular, and molecular aspects of arterial calcification 57A
Raul J. Guzman, MD, Nashville, Tenn
Chapter 9
The role of nitric oxide in the pathophysiology of intimal hyperplasia 64A
Sadaf S. Ahanchi, MD, Nick D. Tsihlis, PhD, and Melina R. Kibbe, MD, Chicago, Ill
Chapter 10
Molecular engineering of vein bypass grafts 74A
Michael S. Conte, MD, Boston, Mass
Chapter 11
Genomic and proteomic determinants of lower extremity revascularization failure: Rationale and study design 82A
Peter R. Nelson, MD, Kerri A. O’Malley, PhD, Robert J. Feezor, MD, Lyle L. Moldawer, PhD, and James M. Seeger, MD, Gainesville, Fla
Chapter 12
Cytokines and the early vein graft: Strategies to enhance durability 92A
C. Keith Ozaki, MD, Gainesville, Fla
Chapter 13
Tissue engineering applications to vascular bypass graft development: The use of adipose-derived stem cells 99A
Paul DiMuzio, MD, and Thomas Tulenko, PhD, Philadelphia, Pa
Chapter 14
Novel thromboresistant materials 104A
Sumanas W. Jordan and Elliot L. Chaikof, MD, PhD, Atlanta, Ga
Chapter 15
Molecular characterization of post-thrombotic syndrome 116A
Lornie J. Phillips II, MD, and Rajabrata Sarkar, MD, PhD, San Francisco, Calif
Chapter 16
Assessing the effectiveness of endografts: Clinical and experimental perspectives 123A
Larisse K. Lee, MD, and Peter L. Faries, MD, New York, NY
Chapter 17
Impact of outcomes research on the management of vascular surgery patients 131A
John E. Rectenwald, MD, and Gilbert R. Upchurch, Jr, MD, Ann Arbor, Mich
Chapter 18
Functional outcome of critical limb ischemia 141A
Gregory J. Landry, MD, Portland, Ore
Chapter 19
Percutaneous treatment of peripheral vascular disease: The role of diabetes and inflammation 149A
Louis L. Nguyen, MD, MBA, MPH, Boston, Mass
Chapter 20
Randomized clinical trials: How will results influence clinical practice in the management of symptomatic and asymptomatic extracranial carotid occlusive disease? 158A
Robert W. Hobson II, MD, Newark, NJ
PII: S0741-5214(07)00713-6
doi:10.1016/S0741-5214(07)00713-6
